ALKERMES | ALKS - Assets

Stock Price
34.91
Daily Change
1.02 3.01%
Monthly
24.68%
Yearly
13.49%
Q1 Forecast
32.88

ALKERMES reported $2.33B in Assets for its fiscal quarter ending in September of 2025.





Assets Change Date
AbbVie USD 133.9B 3.28B Sep/2025
Acadia Pharmaceuticals USD 1.33B 105.22M Sep/2025
ALKERMES USD 2.33B 76.7M Sep/2025
Amgen USD 90.14B 2.24B Sep/2025
Biogen USD 29.21B 877.3M Sep/2025
BioMarin Pharmaceutical USD 7.61B 158.53M Sep/2025
Bristol-Myers Squibb USD 96.89B 2.21B Sep/2025
Eli Lilly USD 114.94B 14.01B Sep/2025
Gilead Sciences USD 58.53B 2.81B Sep/2025
Ionis Pharmaceuticals USD 3.03B 47.96M Sep/2025
J&J USD 192.82B 573M Sep/2025
Malin Corporation EUR 198.5M 70.1M Dec/2024
Merck USD 129.55B 12.02B Sep/2025
Neurocrine Biosciences USD 4.27B 375.9M Sep/2025
Otsuka Holdings JPY 3.96T 170.24B Sep/2025
Pfizer USD 208.73B 2.64B Sep/2025
Regeneron Pharmaceuticals USD 40.56B 389.3M Dec/2025
Vertex Pharmaceuticals USD 24.86B 825.6M Sep/2025